Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (March 2026)
39 slides from Recce Pharmaceuticals's investor presentation, Mar 19, 2026
Slide 1: RCE Webinar
RCE Webinar ASX:RCE | FSE:R9Q March 2026 0
Slide 2: Disclaimer
Disclaimer DISCLAIMER FUTURE MATTERS This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of not purport to contain all the information that a prospecti
Slide 3: Company Overview
Company Overview Introduction James Graham Chief Executive Officer
Slide 4: Recce Pharmaceuticals – Company Overview
Recce Pharmaceuticals – Company Overview An Australian clinical-stage biotech with a United States presence, developing a New Class of Synthetic Anti-infectives with a unique mechanism of action for a broad spectrum of infections including serious/life-threatening indications. • Publicly-traded on t
Slide 5: Board and Management Structure
Board and Management Structure Dr John Prendergast – Chairman BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Michele Dilizia – Executive Director & Chief Scientific Officer BSc (Med Sc i), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of Palatin Technologies,
Slide 6: The Advantages of a New Class of Antibiotics
The Advantages of a New Class of Antibiotics Recce is on-track to be the only global clinical stage company whose drug is shown to be efficacious against the full suite of ESKAPE pathogens Unprecedented, broad-spectrum activity against Gram-positive and Gram-negative bacteria Universal Mechanism of
Slide 7: RECCE® 327 Clinical Programs
RECCE® 327 Clinical Clinical Overview Programs Dr Alan W Dunton Chief Medical Advisor & Non-Executive Director 6
Slide 8: DFIs: Addressing a High-Burden Infection Setting
DFIs: Addressing a High-Burden Infection Setting DFIs are complex infection Local infection RECCE® 327 Gel was designed environments management in DFIs with DFI complexity in mind • Compromised blood flow, impaired • Direct delivery of anti-infective • Designed for direct application immune response
Slide 9: RECCE® 327 Topical Gel
RECCE® 327 Topical Gel First-Line Local Treatment for Infected Wounds No Pathogen Identification Required Rapid Clinical Response • Applied directly to infected tissue • Clinical and TGA Special Access Scheme use demonstrates visible reduction in • Localised antimicrobial action at the site of infec
Slide 10: Topical Clinical Programs – Previously Completed
Topical Clinical Programs – Previously Completed • Interim data results released – primary endpoints achieved Phase I/II • Patients supported by in-home (out-patient) nurses trained in Clinical Trial R327 treatment protocols Diabetic Foot • Study across South Western Sydney health district – one of
Slide 11: Phase II ABSSSI Clinical Trial
Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Clinical Trial Successful clinical response Achieved all Endpoints • This Phase II study achieved all primary and secondary endpoints as an open-label After 7 days of treatment clinical trial evaluating the safety and tolerability,
Slide 12: Registrational Phase 3 Clinical Trial - Indonesia
Registrational Phase 3 Clinical Trial - Indonesia Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Infections Timeline 2026 2027 Phase 3 Interim Data Readout - 155 patients R327 Topical Diabetic Foot Ulcer Infection GEL Indo trial data INDONESIA/
Slide 13: Etana & Recce Program Overview
Etana & Recce Program Overview Nathan Tirtana Chief Executive Officer – Etana Biotechnologies 12
Slide 14: PT Etana Biotechnologies – Company Overview
PT Etana Biotechnologies – Company Overview Innovative, affordable biopharmaceuticals for Indonesia — in collaboration with Recce Pharmaceuticals • Founded in 2014 – emerging producer of innovative, affordable biopharmaceuticals. • Focus areas: Infectious disease & other life-threatening diseases, c
Slide 15: Strategic Partnership in South-East Asia to Accelerate Clinical Program
Strategic Partnership in South-East Asia to Accelerate Clinical Program • Recce and leading biomedical organisation PT Etana Biotechnologies Memorandum of Understanding (MoU). • MoU aims to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian Government’s access to novel inf
Slide 16: Registrational Phase 3 Clinical Trial - Indonesia
Registrational Phase 3 Clinical Trial - Indonesia Study Title: Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections Population Up to 310 participants will Intervention be enrolled who present with a mild diabetic foot infection. Part
Slide 17: Siloam Hospitals Trial Site Overview
Siloam Hospitals Trial Site Overview ® Dr RECCE Jane Olivia Lorens 327 Clinical Research Department Head – Topical Gel Siloam Clinical Research Siloam Hospitals – Introduction Industry Engagement in Indonesia Regulatory Acceleration & ASEAN Commercial Entry 16
Slide 18: Dept. of War RECCE Burn Wound Clinical Programs
Dept. of War RECCE ® 327 Burn Wound Clinical Programs Programs David F. Lasseter Founder and Partner of Horizons Global Solutions Ryan Kane Founder and Managing Partner of RK Strategies, Inc. 20
Slide 19: Speakers
Speakers David F. Lasseter is the Founder and Partner of Horizons Global Solutions, a consultancy specializing in national security, law enforcement, intelligence and biotechnology. He served as the Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction (CWMD), suppo
Slide 20: US Defense Areas of Interest
US Defense Areas of Interest ✓ Antimicrobials – MDR Bacteria and Biothreat Pathogens Broad Research Theme: seeking ✓ Burn and Blast Medical Countermeasures unconventional approaches outside the ✓ Combat Wound infections mainstream that challenge assumptions and have the potential to radically change
Slide 21: Applications for the Warfighter
Applications for the Warfighter Proof-of concept The Challenge The Solution • Military personnel are vulnerable to the morbidity and mortality • An acute intervention for military burn wounds sustained in a associated with infections resulting from burn wounds sustained combat setting during combat.
Slide 22: US Department of War Overview
US Department of War Overview U.S. Department of Defense CRADA with the U.S. CRADA with the U.S. Army Congressionally Directed Army Medical Research Institute of Surgical Medical Research Program Institute of Infectious Research (USAISR) (CDMRP) Diseases Project: A Novel, Synthetic Anti-infective Pr
Slide 23: Pre-Clinical Programs
RECCE® 327 ClinicalPrograms Pre-Clinical Programs Michele Dilizia Executive Director & Chief Scientific Officer 25
Slide 24: Contributors to Antibiotic Resistance
Contributors to Antibiotic Resistance • Increased consumption of antimicrobial drugs – Both by humans and animals; and improper prescribing of antimicrobial therapy. 4 • Overuse of many common antimicrobials agents by physicians may occur The emergence and – The choice of drug is based on a combinat
Slide 25: VAP is a Common Infection that Typically Occurs in the ICU
VAP is a Common Infection that Typically Occurs in the ICU High clinical burden given comorbidities associated with hospitalised patients Overview of Ventilator-associated Pneumonia (VAP) Typical Setting of Care Primary route of infection is • VAP typically occurs in the ICU, but may also present in
Slide 26: High unmet need in VAP is driven by significant morbidity and mortality
High unmet need in VAP is driven by significant morbidity and mortality Due to high prevalence of MDR pathogens Physician Perspectives on Key Unmet Needs in VAP DEGREE OF NEED DESCRIPTION PHYSICIAN INSIGHT Decreased Time • Physicians noted that time on mechanical ventilation “Prolonged time on MV ca
Slide 27: R327 Demonstrates Potent Efficacy Against CRAB Lung Infection
R327 Demonstrates Potent Efficacy Against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Lung Infection Model: Hospital-Acquired Pneumonia (HAP) caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB) Design: 40 female mice assigned to 7 groups; treated with R327, placebo, saline, or mero
Slide 28: Tuberculosis Burden in Indonesia
Tuberculosis Burden in Indonesia Tuberculosis is a highly serious and potentially fatal infectious disease that continues to pose a major global health challenge. • Tuberculosis continues to represent a major global unmet medical need, with ~10.8 million new cases annually worldwide.¹ • Indonesia ac
Slide 29: Mycobacterium fortuitum
Mycobacterium fortuitum • Objective: The aim of the study was to evaluate the efficacy of Time course of bacterial load in kidneys of mice R327A and R327B against Mycobacterium fortuitum treated with reference and test compounds (ATCC6841TM) in the mouse intravenous infection model. • Results: Both
Slide 30: RECCE® 327 broad activity against a range of clinical MDR species
RECCE® 327 broad activity against a range of clinical MDR species Nos of strains susceptible to Nos of strains susceptible # of strains R327/susceptible to to R327/resistant to resistant to R327 comparator abx comparator abx Comparator Total nos abx of strains (+/+) (+/-) Enterococcus ampicillin 51
Slide 31: R327 Faster Acting Than Existing Antibiotics
R327 Faster Acting Than Existing Antibiotics No Prolonged Exposure Needed R327 is faster-acting against bacteria than other antibiotics – works quickly, without prolonged cellular exposure times required of other antibiotics (extended exposures commonly associated with systemic toxicity). R327 desig
Slide 32: Company Overview: What's next
Company Overview What’s next Dr John Prendergast Executive Chairman
Slide 33: The antibacterial pipeline reveals a dual crisis: Scarcity and Lack of Innovation
• The antibacterial pipeline reveals a dual crisis: Scarcity and Lack of Innovation Antibiotic-resistant (WHO Report 2025) infections now contribute to 4.9 million deaths globally each year • Approximately 13 to 17 new antibacterial agents were approved by the FDA between 2017 and mid-2024, with onl
Slide 34: Innovation is critical to combat the global superbug crisis
Other disease areas with high impact Innovation is critical to combat the global innovation superbug crisis PD1 Antibodies- Cancer RECCE 327 (R327) is a GLP-1 Inhibitors fully synthetic polymer This molecule stands out in Obesity designed to disrupt clinical development as the bacterial energy (ATP)
Slide 35: Program Pipeline driven by 1st approval in Diabetic Foot Infections
Program Pipeline* driven by 1st approval in Diabetic Foot Infections 2026 2027 2028 2029 2030 Phase 3 Interim Data Reado ut - 155 patients R327 Topical Diabetic Foot Ulcer Infection GEL INDONESIA/ASEAN Indo tr ial data used fo r global R327G R327G registration strategy Registered Registered in Indon
Slide 36: Commercial Strategy – By Region
Commercial Strategy – By Region EUR Multiple high-value markets with established AMR and DFI treatment pathways. Patent protection de-risks potential commercial partnerships. ASEAN One of the fastest- growing diabetic and wound care USA populations, active Phase 3 pathway. Supports immediate World’s
Slide 37: RECCE: Key Takeaways/Messages
RECCE: Key Takeaways/Messages R327 topical gel formulation R327 targets any bacteria independent acts rapidly at the target site of resistance to other antibiotics unlike oral or IV antibiotics Demonstrates amazing lethality in minutes (not hours or days like traditional No Standard of Care for a to
Slide 38: Recce: Pioneer to Global Leader
Recce: Pioneer to Global Leader With significant value creation opportunities The world’s first synthetic anti-infective platform with programmable polymers for the post-antibiotic age engineered to outsmart superbugs Development of a first new class of antibiotic in over 40 years, recognised by the
Slide 39: Thank you
Thank you @0@ recce.com.au
Recce Pharmaceuticals — Investor Presentation (March 2026) on 6ix